Successful US migraine drug being trialled in the UK
Do you or someone you know suffer with migraines that limit your everyday life? A new drug could put a stop to them
A MIGRAINE drug that has received FDA Approval in the USA can now be accessed by UK sufferers.
REYVOW (lasmiditan) is a migraine medication which is currently undergoing UK clinical trials, and you can take part at Re:Cognition Health clinics in London, Guildford and Birmingham.
Eli Lily, the pharmaceutical company conducting the trial, has received FDA approval for the medication in the USA, meaning that it has proven to be a successful treatment in studies in the USA and will soon be available on the market to patients in the States.
Reyvow is a new treatment for acute migraines, an extremely painful condition which affects up to six million Britons each year. The efficacy of this treatment in the USA was demonstrated in two randomized, double-blind, placebo-controlled trials on 3,177 study volunteers.
The medication targets pain and other migraine symptoms such as nausea, light and sound sensitivity.
Whilst Reyvow is still undergoing UK and European studies, this approval is a huge step forward in treating people with acute migraine.
Dr Emer MacSweeney, Consultant Neuroradiologist at Re:Cognition
Health, said: “It’s always fantastic news when a clinical trial has a successful outcome and we are delighted to hear that REYVOW has received FDA approval in the USA.
“We are optimistic that this treatment will have the same successful outcome in the UK studies. Our team of Brain & Mind Experts are proud to be giving volunteers in the UK the opportunity to be part of this extremely important research, as well giving them early access to this newgeneration medication, which can be life-changing for many people who suffer from migraine attacks.”
Re:Cognition Health is committed to research and finding new treatments and ultimately a cure for migraine through our ongoing clinical trials. We are proud to be spearheading new studies such as this migraine trial and helping improve the quality of life for millions of people worldwide.
Migraine is extremely common in the UK and can be triggered by a multitude of factors ranging from genetics, food intolerances and allergies through to hormones, lifestyle, weather conditions, environment and wider medical issues.
Migraines can be debilitating and seriously impede the quality of life for the six million Britons who suffer from them every year.
As one of the biggest causes of work absenteeism in the UK, migraines cost the economy over £2.25 billion per year with 25 million lost days of work. It is estimated to cost the NHS £150million per year in prescription medication.
Ranked globally as the seventh most disabling disease, migraine is the least publicly funded neurological illnesses in respect to its economic impact.
A migraine is effectively a severe, throbbing headache accompanied by symptoms which can include nausea, vomiting, sensitivity to light and sound with pain varying in intensity and duration, ranging from a few hours through to days.
You’ll find Re:Cognition Health at 77 Wimpole Street London W1G 9RU 0203 355 3536 or visit www.brainandmindexperts.com/